MedPath

ACB A Randomized Study of 2.5ug/kg/Day vs. 5ug/kg/Day Dose of G-CSF After High Dose Chemotherapy Followed by Autologous Peripheral Blood Stem Cell/Marrow Transplant Recipients FILE#17159

Not Applicable
Completed
Conditions
Peripheral Stem Cell/Marrow Transplant
Registration Number
NCT00168168
Lead Sponsor
Alberta Health services
Brief Summary

Evaluate recovery time on 2.5 mg/Kg/day dose of G-CSF versus 5 mg/Kg/day dose.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
60
Inclusion Criteria
  • over age 18
  • autologous stem cell/marrow transplant candidate in MM, lymphoma, AMG and testicular
Exclusion Criteria
  • age below 18 years
  • sensitive to G-CSF

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Cross Cancer Institute

🇨🇦

Edmonton, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath